Acousia Therapeutics GmbH

Acousia Therapeutics Reaches 50% Enrollment in Phase 2 Trial for Cisplatin-Induced Hearing Loss Prevention

a month ago

• Acousia Therapeutics has enrolled 50% of patients in its Phase 2 PROHEAR Study testing ACOU085 (bimokalner) to prevent cisplatin-induced hearing loss in testicular cancer patients undergoing chemotherapy. • The innovative split-body trial design administers ACOU085 to one ear and placebo to the other in each participant, with all patients receiving high-dose cisplatin (≥300 mg/m²) developing ototoxicity, highlighting the urgent need for preventive treatments. • The study is being conducted across 13 German ENT university clinics with enrollment expected to complete by late 2025, representing a significant advancement in addressing a major unmet need affecting up to 80% of cisplatin-treated patients.